GGrantIndex
← Leaderboards

Peter L Jones

University Of Nevada Reno

$12,832,107
Attributed
$12,832,107
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY200725
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,832,107 · 7

By mechanism

R01$11,791,335 · 4
R21$771,252 · 2
K22$269,520 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Affect

Research focus

AffectGenesMyopathyD4z4Epigenetic ProcessChromosomesMediatingGene ExpressionMusclePathology4q35Facioscapulohumeral Muscular DystrophyPathogenesisAnimal ModelGeneticPathway InteractionsIn VivoCellsComplexAdultMouse ModelProteinsPhenotypeRegulation

Grant awards (35)

CRISPR-inhibition for FSHD$517,866
R01 · FY2025 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$572,861
R01 · FY2024 · AR · contact PI
CRISPR-inhibition for FSHD$517,866
R01 · FY2024 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$605,201
R01 · FY2023 · AR · contact PI
CRISPR-inhibition for FSHD$533,883
R01 · FY2023 · AR · contact PI
Accessible FSHD diagnostics through epigenetic analysis$193,951
R21 · FY2023 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$600,403
R01 · FY2022 · AR · contact PI
CRISPR-inhibition for FSHD$526,259
R01 · FY2022 · AR · contact PI
Accessible FSHD diagnostics through epigenetic analysis$171,951
R21 · FY2022 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$588,273
R01 · FY2021 · AR · contact PI
CRISPR-inhibition for FSHD$538,881
R01 · FY2021 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$617,468
R01 · FY2020 · AR · contact PI
Pathogenic Mechanisms in Facioscapulohumeral Muscular Dystrophy$403,786
R01 · FY2020 · AR · contact PI
Pathogenic Mechanisms in Facioscapulohumeral Muscular Dystrophy$403,786
R01 · FY2019 · AR · contact PI
Pathogenic Mechanisms in Facioscapulohumeral Muscular Dystrophy$533,748
R01 · FY2018 · AR · contact PI
Pathogenic Mechanisms in Facioscapulohumeral Muscular Dystrophy$533,748
R01 · FY2017 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$425,325
R01 · FY2017 · AR · contact PI
Establishing an FSHD-like Mouse for Therapeutic Development$221,100
R21 · FY2017 · AR · contact PI
Pathogenic Mechanisms in Facioscapulohumeral Muscular Dystrophy$380,443
R01 · FY2016 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$310,584
R01 · FY2016 · AR · contact PI
Pathogenic mechanisms in facioscapulohumeral muscular dystrophy$170,180
R01 · FY2016 · AR · contact PI
Establishing an FSHD-like Mouse for Therapeutic Development$166,888
R21 · FY2016 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$156,811
R01 · FY2016 · AR · contact PI
Establishing an FSHD-like mouse for therapeutic development$17,362
R21 · FY2016 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$485,147
R01 · FY2015 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$485,147
R01 · FY2014 · AR · contact PI
Mechanisms of DUX4 mediated FSHD pathology$499,626
R01 · FY2013 · AR · contact PI
Molecular mechanism of FSHD pathology$260,287
R01 · FY2011 · AR · contact PI
Molecular mechanism of FSHD pathology$39,971
R01 · FY2011 · AR · contact PI
Molecular mechanism of FSHD pathology$322,536
R01 · FY2010 · AR · contact PI
Molecular mechanism of FSHD pathology$249,796
R01 · FY2009 · AR · contact PI
Molecular mechanism of FSHD pathology$253,022
R01 · FY2008 · AR · contact PI
Molecular mechanism of FSHD pathology$258,431
R01 · FY2007 · AR · contact PI
METHYLATION-DEPENDENT TRANSCRIPTIONAL REPRESSION$135,000
K22 · FY2003 · HD
METHYLATION-DEPENDENT TRANSCRIPTIONAL REPRESSION$134,520
K22 · FY2002 · HD